Back to top
more

Exelixis (EXEL)

(Delayed Data from NSDQ)

$22.40 USD

22.40
1,189,759

-0.15 (-0.67%)

Updated Jul 12, 2024 04:00 PM ET

After-Market: $22.41 +0.01 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Wall Street Analysts Predict a 74% Upside in Exelixis (EXEL): Here's What You Should Know

by Zacks Equity Research

The mean of analysts' price targets for Exelixis (EXEL) points to a 74% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

EXEL vs. TECH: Which Stock Is the Better Value Option?

by Zacks Equity Research

EXEL vs. TECH: Which Stock Is the Better Value Option?

Should Value Investors Buy Exelixis (EXEL) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Biotech Stock Roundup: ICPT, KALV Down on Study Data, VIR Up on Contract Win & More

by Zacks Equity Research

Regulatory and pipeline updates from ICPT and KALV are the key highlights from the biotech sector during the past week.

Is Exelixis' (EXEL) Growth Story Likely to Continue?

by Zacks Equity Research

Exelixis' (EXEL) efforts to expand Cabometyx's label and develop additional drugs to expand its portfolio should reap rewards for the company.

Exelixis (EXEL) Reports Positive Cabometyx Combo Study Results

by Zacks Equity Research

Exelixis (EXEL) announces positive detailed results on the triplet combination study of Cabometyx, Opdivo and Yervoy.

Why Is Exelixis (EXEL) Down 8.8% Since Last Earnings Report?

by Zacks Equity Research

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Should iShares Morningstar SmallCap Growth ETF (ISCG) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for ISCG

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Exelixis (EXEL) Q2 Earnings Beat, Cabometyx Maintains Growth

by Zacks Equity Research

Exelixis (EXEL) tops earnings and sales in the second quarter as lead drug Cabometyx maintains momentum.

Exelixis (EXEL) Beats Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Exelixis (EXEL) delivered earnings and revenue surprises of 10% and 7.25%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Atara Biotherapeutics (ATRA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of 65.93% and 483.28%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Drug, Biotech Stocks' Q2 Earnings on Aug 9: EXEL, BHC & More

by Kinjel Shah

Let us look at four drug and biotech companies, EXEL, BHC, CPRX and AXSM, which are gearing up for their earnings release.

Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of -5.81% and 68.17%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

G1 Therapeutics (GTHX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 11.54% and 17.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Exelixis (EXEL) to Post Q2 Earnings: What is in the Cards?

by Zacks Equity Research

Investors will likely focus on the demand for Cabometyx and pipeline updates when Exelixis (EXEL) reports Q2 results. Operating expenses might have jumped.

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

by Zacks Equity Research

Sector ETF report for FBT

Exelixis (EXEL) Cabometyx Combo Study Meets Primary Goal

by Zacks Equity Research

Exelixis'(EXEL) late-stage study evaluating the combination of Cabometyx and Opdivo and Yervoy demonstrates significant improvement in progression-free survival at the primary analysis.

Exelixis (EXEL) Collaborates With Ryvu for Cancer Therapies

by Zacks Equity Research

Exelixis (EXEL) teams up with Ryvu Therapeutics to develop novel STING agonist-based targeted cancer therapies.

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for FBT

Exelixis (EXEL) Outperforms Industry in 1H22: What Lies Ahead?

by Zacks Equity Research

Exelixis (EXEL) outperforms the industry in the year so far on Cabometyx performance and pipeline progress.

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

by Zacks Equity Research

Sector ETF report for XBI

Why Exelixis (EXEL) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Exelixis (EXEL) Begins Study on XL092 Combo in Colorectal Cancer

by Zacks Equity Research

Exelixis (EXEL) starts the phase III STELLAR-303 study evaluating XL092 in combination with atezolizumab as compared to regorafenib for treating patients with metastatic colorectal cancer.